课题基金 / 基金详情

Integrative elucidation of molecular mechanisms for leukemogenesis: Identification and analyses of mutations with novel categories.

Integrative elucidation of molecular mechanisms for leukemogenesis: Identification and analyses of mutations with novel categories.
白血病发生分子机制的综合阐明:新类别突变的识别和分析。
批准号:
23249051
负责人:
KITAMURA Toshio
金额:
$30.7万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2011
资助国家:
日本
项目状态:
已结题
起止时间:
2011-05-31 至 2014-03-31

项目摘要

项目成果

KITAMURA Toshio的其他基金

相似基金

相关文献

中文摘要
翻译
各种表观遗传因素的突变最近在各种血液恶性肿瘤中被发现。我们已经证明TET2、EZH2或ASXL1突变在小鼠骨髓移植(BMT)模型中诱导骨髓增生异常综合征(MDS)样,并且ASXL1突变体通过EZH2/PRC2抑制诱导HoxA9和miR125a的降低在诱导MDS样疾病中起关键作用。我们之前报道过Hes1在CML-BC中起关键作用。我们在这里证明了Hes1通过NFkB激活诱导MMP9表达在CML-BC的进展中起一定作用。此外,我们还证明了Hes1与FIP1L1-PDGFR协同诱导小鼠BMT模型中的AML,并且在5例携带FIP1L1-PDGFR的嗜酸性白血病患者中有2例观察到Hes1过表达。这些结果表明Hes1在抑制髓细胞分化中参与了白血病的发生。
英文摘要
Mutations in a variety of epigenetic factors have been recently identified in various hematological malignancies. We have demonstrated that the mutations in TET2, EZH2 or ASXL1 induce myelodysplastic syndromes (MDS)-like in mouse bone marrow transplant (BMT) model and that derepression of HoxA9 and miR125a induced by ASXL1 mutants via EZH2/PRC2 repression plays critical roles in inducing MDS-like disease.We previously reported that Hes1 plays critical roles in CML-BC. We here demonstrate that MMP9 expression induced by Hes1 via NFkB activation plays some roles in the progression of CML-BC. In addition, we also demonstrated that Hes1 collaborated with FIP1L1-PDGFR in inducing AML in mouse BMT model and that Hes1 overexpression was observed in 2 of 5 patients with eosinophilic leukemia harboring FIP1L1-PDGFR. These results indicate that Hes1 contribute to leukemogenesis in suppressing myeloid differentiation.
期刊论文(60)
专著(0)
科研奖励(0)
会议论文
HDACI-induced thrombocytopenia is caused by its unexpected target.
HDACI 诱导的血小板减少症是由其意想不到的靶标引起的。
DOI: 10.1016/j.exphem.2012.07.001
发表时间: 2012
期刊: Experimental hematology
影响因子: 2.6
作者: [北村俊雄, 井上大地]
通讯作者: 井上大地
Nov/CCN3 Enhances Long-Term Repopulating Activity of-Mouse Hematopoietic Stem Cells Via Intergin β3 Signaling Collaborating with Thrombopoietin
Nov/CCN3 通过 Intergin β3 信号传导与血小板生成素协同增强小鼠造血干细胞的长期再生活性
DOI: --
发表时间: 2011
期刊:
影响因子: --
作者: [Kono M, Sugiura K, Suganuma M, Hayashi M, Takama H, Suzuki T, Matsunaga K, Tomita Y, Akiyama M., Jun Ishihara]
通讯作者: Jun Ishihara
Leukemogenesis induced by C-terminal mutations in the basic leucine zipper domain of C/EBPα
C/EBPα 基本亮氨酸拉链结构域 C 端突变诱导的白血病发生
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [戸上勝仁, 北浦次郎, 井上大地, 鍵山侑希, 内田智之, 西村耕太郎, 土岐典子, 加藤菜穂子, 中原史雄, 沖俊彦, 原田結花, 原田浩徳, 北村俊雄]
通讯作者: 北村俊雄
Two forms of C/EBPa mutants collaborate in leukemogenesis.
两种形式的C/EBPα突变体在白血病发生中协同作用。
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [Takayama K, Inoue S, Ohdan H, Toshio Kitamura]
通讯作者: Toshio Kitamura
44
    Analysis of relationship between nuclear segmentation and gene expression using neutrophils and ATL cells
    • 批准号:
      23659485
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      KITAMURA Toshio
    • 依托单位:
    Toward the comprehensive understanding of molecular mechanisms of hematopoietic malignancies
    • 批准号:
      20249051
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $31.12万
    • 财政年份:
      2008
    • 负责人:
      KITAMURA Toshio
    • 依托单位:
    Crosstalk between STATs and small GTPases in the control of cell division and differentiation.
    • 批准号:
      16209032
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $31.03万
    • 财政年份:
      2004
    • 负责人:
      KITAMURA Toshio
    • 依托单位:
    Pleiotropic functions of cytokines and STAT5
    • 批准号:
      13470070
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $7.55万
    • 财政年份:
      2001
    • 负责人:
      KITAMURA Toshio
    • 依托单位:
    国内基金
    海外基金
    瘤内链球菌促进STAT3的O-GlcNAc修饰驱动鼻咽癌免疫抑制微环境的机制研究
    • 批准号:
      JCZRLH202600778
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    SDC1通过MMP11+CAF的细胞外基质重塑促进子宫颈癌化学免疫联合治疗耐药的机制研究
    • 批准号:
      JCZRQNB202600504
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    多模态精准导航引导肝内胆管癌淋巴结清扫的动态示踪与机制探索
    抗BNLF2b抗体联合circRNA构建鼻咽癌早期诊断模型及机制研究